Leap Therapeutics has initiated Part B of the DeFianCe Phase II study to assess DKN-01 along with bevacizumab and chemotherapy as a second-line treatment for patients with advanced colorectal cancer (CRC).
The randomised controlled Part B of the study intends to enrol 130 patients with advanced CRC.
Progression-free survival is the primary objective of the study while overall survival, duration of response, and overall response rate are secondary objectives.
Leap plans to start enrolling patients for Part B in the upcoming 12 months and announce initial data late next year.
Leap Therapeutics chief medical officer Cynthia Sirard said: “The study enrolled quickly and has already exceeded the 20% overall response rate threshold.
“After the planned safety review meeting with our investigators, we decided to initiate the randomised controlled study.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
“We continue to follow these Part A patients to assess the durability of response, progression-free survival, and to determine whether additional patients with stable disease may become responders over time.”
The initiation of Part B is based on the early efficacy results from Part A, which included 33 patients who were previously exposed to standard-of-care bevacizumab and had early progression on first-line therapy.
Patients who had tumours harbouring Ras mutations or liver metastases were also included in Part A of the study.
DKN-01, a humanised monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, is in development for treating patients with esophagogastric and gynecologic cancers along with CRC.
Leap’s portfolio also includes a humanised monoclonal antibody targeting Claudin18.2, FL-301, designed for treating gastric and pancreatic cancer.